A bold vision and a transformative approach, driven by our deep expertise.
Our Management, Board of Directors, and Scientific Advisory Board are comprised of world-class GI and autoimmune experts. Most with the experience and knowledge gained at large pharmaceutical companies and adapted to our unique culture of innovation and agility. All united by their desire to improve the treatment paradigm by developing targeted therapies.
The key to success is in our people
Our team is comprised of true innovators in the field who are passionate about changing the way we treat IBD and immune-mediated diseases.
Mark C. McKenna
Keith W. Marshall, Ph.D.
Keith W. Marshall, Ph.D., has served as our Chief Financial Officer since August 2020. Previously, he served as Executive Vice President, Chief Operating Officer, and Chief Financial Officer of Conatus Pharmaceuticals from 2017 to 2020 and as Chief Financial Officer and Head of Corporate Development at Torque Therapeutics, now Repertoire Immune Medicines, from 2015 to 2017. Before moving into industry, Dr. Marshall spent 15 years in healthcare investment banking primarily focused on financings and M&A.
Dr. Marshall holds an A.B. from Washington University in St. Louis, a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco, and an MBA from the University of Chicago Booth School of Business.
Olivier Laurent, Ph.D.
Chief Scientific Officer
Head of R&D
Allison Luo, M.D.
Timothy K. Andrews